MoonLake Immunotherapeutics MLTX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's financing cash flow?
- MoonLake Immunotherapeutics (MLTX) reported financing cash flow of $30.64M in Q1 2026.
- How has MoonLake Immunotherapeutics's financing cash flow changed year-over-year?
- MoonLake Immunotherapeutics's financing cash flow decreased by 58.1% year-over-year, from $73.12M to $30.64M.
- What is the long-term trend for MoonLake Immunotherapeutics's financing cash flow?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's financing cash flow has grown at a 19.5% compound annual growth rate (CAGR), from $71.53M to $146M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.